Везде
STRATEGIC DIRECTIONS OF THE U.S. PHARMACEUTICAL COMPANIES DEVELOPMENT
Table of contents
Annotation Estimate Publication content
References Comments
Share
QR
Metrics
STRATEGIC DIRECTIONS OF THE U.S. PHARMACEUTICAL COMPANIES DEVELOPMENT
Annotation
PII
S268667300000616-7-1
Publication type
Article
Status
Published
Authors
Dmitry Raspopov 
Edition
Issue 9 (537)
Pages
83-94
Abstract
The article gives an overview of the major trends on the global pharmaceutical market as well as key factors that have strong effect on it. International competitiveness of U.S. pharmaceutical firms is analyzed and their major strategic directions are defined.
Keywords
pharmaceutical market, strategy, mergers and acquisitions, patent cliff, generics, biosimilars, blockbuster
Date of publication
11.09.2014
Number of purchasers
1
Views
765
Readers community rating
0.0 (0 votes)
Cite   Download pdf

References



Additional sources and materials

1. Lin A.A., Sokolova S.V. Farmatsevticheskij rynok: fundamental'nye osobennosti / Problemy sovremennoj ehkonomiki. 2012. № 2 (42). 
 2. Ovcharov E.G. Mirovaya farmatsevticheskaya promyshlennost': sovremennoe sostoyanie i tendentsii razvitiya v usloviyakh globalizatsii. Dis. na soiskanie uchenoj stepeni kand. ehkonom. nauk: 08.00.14 / Ovcharov Evgenij Gennad'evich. M., 2005. 60 s. 
 3. Tashenov A. Tendentsii razvitiya mirovogo farmatsevticheskogo rynka [Ehlektronnyj resurs] / Evrazijskij bank razvitiya. 2013 (http://www.eabr.org/r/research/publication/today/index.php?id_4=33620).
 4. Farmatsevticheskaya promyshlennost' i global'noe zdravookhranenie: fakty i tsifry. M., 2012. 8 s.
 5. Bruno Calo-Fernández, Juan Leonardo Martínez-Hurtado. Biosimilars: Company Strategies to Capture Value from the Biologics Market. 2012 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816668/).
 6. Cancer Explosion Forecast for Next 20 years. 2013 (http://ens-newswire.com/2014/02/04/cancer-explosion-forecast-for-next-20-years/).
 7. EvaluatePharma. Returning to Growth. World Preview 2013, Outlook to 2018. 2013 (http://www.evaluategroup.com).
 8. EU Industrial R&D Investment Scoreboard. 2013. P. 40-45.
 9. Frost & Sullivan. Analysis of the Global Biosimilars Market. 2014 (www.frost.com). 
 10. Generic Pharmaceutical Association. Generic Drug Savings in the U.S. 2013 (http://www.gphaonline.org/media/cms/2013_Savings_Study_12.19.2013_FINAL.pdf).
 11. IDF Diabetes Atlas. 2013 (http://www.idf.org/diabetesatlas).
 12. Johnson & Johnson Innovation Expands Global Incubator Presence to Israel and Announces Multiple, Diverse, Early-Stage Collaborations with Academia and Biotech (http://www.jnj.com/news/product/Johnson-Johnson-Innovation-Expands-Global-Incubator-Presence-to-Israel-and-Announces-Multiple-Diverse-Early-Stage-Collaborations-with-Academia-and-Biotech).
 13. Mergers and Acquisitions in Pharmaceutical Industry (http://www.ukessays.com/essays/finance/mergers-and-acquisitions-in-pharmaceutical-industry-finance-essay.php).
 14. Mylan-Biocon Receive First Indian Biosimilar Regulatory Approval for Herceptin (http://investor.mylan.com/releasedetail.cfm?ReleaseID=809392).
 15. Pharmaceutical Executive. 2002 (http://www.pharmexec.com/pharmexec/data/articlelong/pharmexec/182002/17966/article.pdf).
 16. Pharmaceutical Executive. 2013 (http://www.pharmexec.com/pharmexec/Noteworthy/The-2013-Pharm-Exec-Top-50/ArticleStandard/Article/detail/815158).
 17. Top-50 Pharmaceutical Companies (http://www.currentpartnering.com/insight/top-50-pharma/).
 18. Tufts Center for the Study of Drug Development. Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically. 2013. Vol. 15. No. 6.
 19. Will Biobetters Beat Biologics? (http://social.eyeforpharma.com/forecasting/will-biobetters-beat-biologics).
 20. World Consumer Income and Expenditure Patterns. 2013. P. 69. Table 3.4 (http://www.euromonitor.com/medialibrary/PDF/Book_WCIEP0.pdf).

Comments

No posts found

Write a review
Translate